Payment overview · 2025
General Payments
$306.20
17 reported records · 7 companies
Healthcare provider profile · identity verified
Michael Hancock, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BOONEVILLE, MS · NPI 1104236504
Verified facts
What the public records show
CMS Open Payments records show Michael Hancock, M.D. received $306.20 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 44.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $135.13 | 44.1% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.04 | 18.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.68 | 8.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.18 | 7.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $23.95 | 7.8% | 1 | 2025 |
| Fisher & Paykel Healthcare Inc | Unresolved — no canonical attribution shown | $23.14 | 7.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.08 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $306.20 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $88.04 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $57.04 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.84 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $47.09 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| FISHER & PAYKEL HEALTHCARE Normalized: fisher paykel healthcare |
Device | Fisher & Paykel Healthcare Inc | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
96 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 739 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 551 | 94 |
| Gabapentin | Gabapentin | 510 | 83 |
| Potassium Chloride | Potassium Chloride | 502 | 85 |
| Furosemide | Furosemide | 501 | 93 |
| Trazodone Hcl | Trazodone Hcl | 472 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 376 | 74 |
| Lisinopril | Lisinopril | 350 | 67 |
| Omeprazole | Omeprazole | 350 | 59 |
| Donepezil Hcl | Donepezil Hcl | 329 | 55 |
| Eliquis | Apixaban | 315 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 310 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 308 | 43 |
| Buspirone Hcl | Buspirone Hcl | 299 | 42 |
| Losartan Potassium | Losartan Potassium | 287 | 52 |
| Famotidine | Famotidine | 278 | 43 |
| Metformin Hcl | Metformin Hcl | 269 | 49 |
| Mirtazapine | Mirtazapine | 259 | 40 |
| Carvedilol | Carvedilol | 224 | 40 |
| Memantine Hcl | Memantine Hcl | 219 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 209 | 30 |
| Sertraline Hcl | Sertraline Hcl | 205 | 30 |
| Montelukast Sodium | Montelukast Sodium | 201 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 41 |
| Ezetimibe | Ezetimibe | 197 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 28 |
| Meloxicam | Meloxicam | 195 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 33 |
| Divalproex Sodium | Divalproex Sodium | 166 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 161 | 27 |
| Allopurinol | Allopurinol | 160 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 155 | 28 |
| Ozempic | Semaglutide | 155 | 32 |
| Jardiance | Empagliflozin | 151 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 132 | 24 |
| Farxiga | Dapagliflozin Propanediol | 125 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 125 | 19 |
| Pregabalin | Pregabalin | 120 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 18 |
| Mounjaro | Tirzepatide | 115 | 20 |
| Tramadol Hcl | Tramadol Hcl | 113 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 28 |
| Meclizine Hcl | Meclizine Hcl | 111 | 26 |
| Spironolactone | Spironolactone | 105 | 18 |
| Finasteride | Finasteride | 102 | 13 |
| Alendronate Sodium | Alendronate Sodium | 100 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 100 | 17 |
| Risperidone | Risperidone | 99 | 12 |
| Baclofen | Baclofen | 98 | 13 |
| Nifedipine Er | Nifedipine | 98 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 98 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 97 | 20 |
| Linzess | Linaclotide | 96 | 14 |
| Torsemide | Torsemide | 96 | 18 |
| Simvastatin | Simvastatin | 93 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 88 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 23 |
| Metformin Hcl Er | Metformin Hcl | 80 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 76 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 76 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 16 |
| Levetiracetam | Levetiracetam | 74 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | suppressed |
| Celecoxib | Celecoxib | 65 | suppressed |
| Rexulti | Brexpiprazole | 64 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 50 |
| Bupropion Xl | Bupropion Hcl | 63 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 18 |
| Bumetanide | Bumetanide | 60 | 13 |
| Aripiprazole | Aripiprazole | 59 | suppressed |
| Lactulose | Lactulose | 59 | 11 |
| Ibuprofen | Ibuprofen | 58 | 18 |
| Methocarbamol | Methocarbamol | 58 | 11 |
| Sucralfate | Sucralfate | 58 | 11 |
| Fenofibrate | Fenofibrate | 56 | 13 |
| Prednisone | Prednisone | 56 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | 14 |
| Novolin R Flexpen | Insulin Regular, Human | 54 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 12 |
| Topiramate | Topiramate | 54 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 51 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 28 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 49 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Olanzapine | Olanzapine | 47 | suppressed |
| Glipizide | Glipizide | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Nystatin | Nystatin | 44 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 36 |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Novolog Flexpen | Insulin Aspart | 41 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 39 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 34 |
| Digoxin | Digoxin | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 35 | suppressed |
| Trulance | Plecanatide | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 16 |
| Incruse Ellipta | Umeclidinium Bromide | 34 | suppressed |
| Metolazone | Metolazone | 34 | 11 |
| Cephalexin | Cephalexin | 33 | 14 |
| Cefdinir | Cefdinir | 32 | 29 |
| Clonidine Hcl | Clonidine Hcl | 32 | 13 |
| Estradiol | Estradiol | 32 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 20 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 28 |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Lubiprostone | Lubiprostone | 28 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 27 | 18 |
| Nurtec Odt | Rimegepant Sulfate | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 26 | 20 |
| Fycompa | Perampanel | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 17 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Novolin R | Insulin Regular, Human | 22 | 13 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Metaxalone | Metaxalone | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 17 | suppressed |
| Veozah | Fezolinetant | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $306.20 · 17 records | Amgen Inc. | AIRSUPRA, EVENITY, FISHER & PAYKEL HEALTHCARE, IBSRELA, INSPIRE, OTEZLA, PROLIA, QULIPTA, REPATHA, REXULTI, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error